tiprankstipranks
Advertisement
Advertisement
Bicara Therapeutics’ Acquisition Strategy Poses Operational, Financing, and Shareholder Dilution Risks
PremiumCompany AnnouncementsBicara Therapeutics’ Acquisition Strategy Poses Operational, Financing, and Shareholder Dilution Risks
14d ago
Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley
Premium
The Fly
Bicara Therapeutics price target raised to $37 from $36 at Morgan Stanley
15d ago
Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs
Premium
The Fly
Bicara Therapeutics price target raised to $18 from $16 at Goldman Sachs
15d ago
Bicara Therapeutics’ Earnings Call Highlights Pivotal Pivot
PremiumCompany AnnouncementsBicara Therapeutics’ Earnings Call Highlights Pivotal Pivot
2M ago
Bicara Therapeutics management to meet with Citizens
Premium
The Fly
Bicara Therapeutics management to meet with Citizens
2M ago
Bicara Therapeutics price target raised to $16 from $11 at Wells Fargo
Premium
The Fly
Bicara Therapeutics price target raised to $16 from $11 at Wells Fargo
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100